Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)). The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include (betaS)-6-(Difluoromethoxy)-beta-[2-oxo-3-[3-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]-3-pyridinepropanoic acid, (S)-3-(6-(Difluoromethoxy)pyridin-3-yl)-3-(2-oxo-3-(3-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid, 3-Pyridinepropanoic acid, 6-(difluoromethoxy)-beta-[2-oxo-3-[3-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]- and (betaS)-. Its PubChem CID is 76899969.
Nesvategrast
| CAS No | 1621332-91-9 |
|---|---|
| Molecular Formula | C23H27F2N5O4 |
| Molecular Weight | 475.5 g/mol |
| Synonyms | (3S)-3-[6-(difluoromethoxy)pyridin-3-yl]-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)). The directory classifies it as a clinical API with a synthetic source/manufacturing origin.
The listed CAS number is 1621332-91-9.
The listed molecular formula is C23H27F2N5O4.
The listed molecular weight is 475.5 g/mol.
(3S)-3-[6-(difluoromethoxy)pyridin-3-yl]-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid.
The source lists (betaS)-6-(Difluoromethoxy)-beta-[2-oxo-3-[3-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]-3-pyridinepropanoic acid, (S)-3-(6-(Difluoromethoxy)pyridin-3-yl)-3-(2-oxo-3-(3-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid, 3-Pyridinepropanoic acid, 6-(difluoromethoxy)-beta-[2-oxo-3-[3-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]- and (betaS)-.